Evolent Health Inc Cl A Com (EVH) Stock Price, Quote & News

Company Profile

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggreg...

Industry: Health Information Services

Sector: Healthcare

Phone: 571 389 6000

Website: www.evolent.com

Address:

1812 N. Moore Street, Suite 1705, Arlington, United States

mp1514 Mar. 21 at 1:00 AM

$EVH The only question I have is where is the bottom??? You think you know where it is and then it drops more.

1 · Reply

PHILMYWALLET Mar. 20 at 9:35 PM

$EVH look at this. Can anyone explain what's going on after hours?

1 · Reply

TOMKiLA Mar. 20 at 2:15 PM

$EVH love this price! 8k shares right now

2 · Reply

StockHunter75 Mar. 20 at 1:48 PM

$EVH Stay away from this SCAM.

1 · Reply

pumpandumpslut Mar. 20 at 1:17 PM

$EVH I am interested at these prices

0 · Reply

St0ckJunkie13 Mar. 19 at 6:25 PM

$EVH Remeber Enron

1 · Reply

TOMKiLA Mar. 19 at 2:25 PM

$EVH we want more news like this! In a statement, Dan McCarthy, president of Evolent, commented, “We are thrilled to have Archie on board to accelerate Evolent’s product strategy. Her deep knowledge of value-based care, health tech and prior authorization, combined with her impressive track record of delivering innovation and AI transformation at scale, made her an ideal hire to drive best-in-class performance for our products and platforms. Our ability to attract visionary leaders such as Archie is a testament to our market leadership, our culture, and our vision to improve the quality and affordability of specialty care.”

0 · Reply

BioTuesdays Mar. 19 at 2:04 PM

$EVH has announced the appointment of healthcare technology leader and AI innovator, Archie Mayani, as chief product officer (CPO). https://biotuesdays.com/2026/03/19/evolent-names-archie-mayani-as-cpo/

1 · Reply

PatBtmn Mar. 18 at 6:01 PM

$EVH out

2 · Reply

riedela Mar. 18 at 5:13 PM

$EVH Rinse and repeat. Loaded big at 2.70. Eventually, it will breakout. Need a new contract or three.

0 · Reply

Evolent announces appointment of Archie Mayani as chief product officer

Feb 26, 2026, 5:00 PM EST - 23 days ago

Evolent to Participate in Upcoming Investor Conferences

Feb 26, 2026, 10:38 AM EST - 23 days ago

Evolent Health: Cheap, Levered, But Ready To Rebound

Feb 25, 2026, 12:27 PM EST - 24 days ago

Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 4:10 PM EST - 25 days ago

Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

Feb 4, 2026, 11:02 AM EST - 6 weeks ago

Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026

Jan 2, 2026, 4:15 PM EST - 2 months ago

Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08

Nov 11, 2025, 10:21 PM EST - 4 months ago

Evolent Health, Inc. (EVH) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 2:46 PM EST - 4 months ago

Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:12 PM EST - 4 months ago

Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden

Nov 6, 2025, 4:10 PM EST - 4 months ago

Evolent Announces Third Quarter 2025 Results

Oct 9, 2025, 8:30 AM EDT - 5 months ago

Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Sep 23, 2025, 4:10 PM EDT - 6 months ago

Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners

PRVA

Aug 21, 2025, 8:35 AM EDT - 7 months ago

Evolent's Soft Q2 Results: Why I'm Holding Anyway

Aug 19, 2025, 7:00 AM EDT - 7 months ago

Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

Aug 18, 2025, 4:05 PM EDT - 7 months ago

Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

Aug 8, 2025, 6:15 PM EDT - 8 months ago

Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:10 PM EDT - 8 months ago

Evolent Announces Second Quarter 2025 Results

Jul 14, 2025, 8:00 AM EDT - 8 months ago

Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 9, 2025, 8:00 AM EDT - 9 months ago

Evolent announces key appointments to leadership team

Jun 20, 2025, 6:30 AM EDT - 9 months ago

Evolent reiterates Q2 and full year guidance for Adjusted EBITDA

May 9, 2025, 6:03 PM EDT - 11 months ago

Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:10 PM EDT - 11 months ago

Evolent Announces First Quarter 2025 Results

Apr 22, 2025, 6:30 AM EDT - 11 months ago

Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors

Apr 15, 2025, 9:00 AM EDT - 1 year ago

Evolent program achieves 20% reduction in use of low-value oncology regimens

Apr 10, 2025, 5:00 PM EDT - 1 year ago

Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025

Feb 20, 2025, 7:28 PM EST - 1 year ago

Evolent Health, Inc. (EVH) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:10 PM EST - 1 year ago

Evolent Announces Fourth Quarter and Full Year 2024 Results

Feb 4, 2025, 7:00 AM EST - 1 year ago

Evolent Health Announces Changes to Board of Directors

Jan 27, 2025, 5:00 PM EST - 1 year ago

Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025

Dec 18, 2024, 4:10 PM EST - 1 year ago

Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

Nov 12, 2024, 2:37 AM EST - 1 year ago

Evolent Health: A Shot At Revival After Market Bruising

Nov 9, 2024, 9:12 AM EST - 1 year ago

Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 8:47 AM EST - 1 year ago

Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session

PINS RDFN SG

Nov 7, 2024, 4:10 PM EST - 1 year ago

Evolent Announces Third Quarter 2024 Results

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Evolent To Release Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Oct 2, 2024, 12:08 PM EDT - 1 year ago

Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2

Aug 23, 2024, 9:00 AM EDT - 1 year ago

Evolent Health: Let The Bidding Begin

Aug 22, 2024, 1:22 PM EDT - 1 year ago

Exclusive: Evolent Health in sale talks after inbound interest, sources say

Aug 8, 2024, 9:18 PM EDT - 1 year ago

Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:10 PM EDT - 1 year ago

Evolent Announces Second Quarter 2024 Results

Jul 11, 2024, 8:00 AM EDT - 1 year ago

Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jun 4, 2024, 7:00 AM EDT - 1 year ago

Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify

May 9, 2024, 4:15 PM EDT - 2 years ago

Evolent and Careology form strategic care navigation partnership to enhance cancer care in the U.S.

May 9, 2024, 4:10 PM EDT - 2 years ago

Evolent Announces First Quarter 2024 Results

Apr 18, 2024, 4:30 PM EDT - 2 years ago

Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Feb 22, 2024, 10:34 PM EST - 2 years ago

Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:10 PM EST - 2 years ago

Evolent Announces Fourth Quarter and Full Year 2023 Results

Feb 14, 2024, 4:10 PM EST - 2 years ago

Evolent Adds Russell Glass, Headspace CEO, to Board of Directors

Jan 25, 2024, 7:00 AM EST - 2 years ago

Evolent to Release Fourth Quarter 2023 Financial Results on Thursday, February 22, 2024

mp1514 Mar. 21 at 1:00 AM

$EVH The only question I have is where is the bottom??? You think you know where it is and then it drops more.

1 · Reply

PHILMYWALLET Mar. 20 at 9:35 PM

$EVH look at this. Can anyone explain what's going on after hours?

1 · Reply

TOMKiLA Mar. 20 at 2:15 PM

$EVH love this price! 8k shares right now

2 · Reply

StockHunter75 Mar. 20 at 1:48 PM

$EVH Stay away from this SCAM.

1 · Reply

pumpandumpslut Mar. 20 at 1:17 PM

$EVH I am interested at these prices

0 · Reply

St0ckJunkie13 Mar. 19 at 6:25 PM

$EVH Remeber Enron

1 · Reply

TOMKiLA Mar. 19 at 2:25 PM

0 · Reply

BioTuesdays Mar. 19 at 2:04 PM

1 · Reply

PatBtmn Mar. 18 at 6:01 PM

$EVH out

2 · Reply

riedela Mar. 18 at 5:13 PM

$EVH Rinse and repeat. Loaded big at 2.70. Eventually, it will breakout. Need a new contract or three.

0 · Reply

BPler Mar. 18 at 3:57 PM

$EVH How many times can you slaughter one ticker?

0 · Reply

buyabdhodler Mar. 18 at 3:48 PM

$EVH wow didn’t think I’d get the chance to buy more here

0 · Reply

PHILMYWALLET Mar. 17 at 9:31 PM

$EVH the only thing we need now is some decent insider-buying. What are you all waiting for? Just give us retail some hope !

0 · Reply

PHILMYWALLET Mar. 17 at 9:20 PM

$EVH just after adding 10k shares. Patience from now until earnings

0 · Reply

BPler Mar. 17 at 12:09 PM

$EVH Brutal how the market shorted this down

0 · Reply

TOMKiLA Mar. 16 at 10:46 PM

$EVH Evolent will have to demonstrate its ability to sign significant deals in the next two quarters, as it typically takes nine to twelve months to see the fruits of a new deal. Assuming $300 million in new deals in two quarters, Evolent would bring a strong wind of positivity, but it will have to demonstrate its ability to grow gross margins and EBITDA. The 2026 figures are ridiculous, but what I really think is that there are no excuses for 2027. From $110-$150 million in EBITDA to at least $270 million in EBITDA, 2027 must be the minimum! Only good luck to all long term investors. With good news and with a lot of new deals, we should expect finally a huge increase of the price stock in the coming 12/15 months!!

0 · Reply

PeakedSeller Mar. 14 at 1:13 PM

$EVH 🔥 Oncology surging to 65% of 2026 revenue + $900M Performance Suite ramp with Highmark partnership firing up. AI savings accelerating + 98% retention rock solid. Crushed near $3 (yes that is a 300 million market cap)— loading this dip hard! 🚀💎 Once the market comes to their senses and rerated this thing like they did back in 2020 (yes I rode that wave too) it will be a crazy move!!!!

0 · Reply

PeakedSeller Mar. 14 at 1:11 PM

$MYGN $EVH my two undervalued healthcare picks for 2026… EVH has a more ayssymmetric upside with higher risk on the debt side. Execution equals 300-500% gain in less than a year MYGN is just a safe double bagger with their new MRD launch (read the data, it’s amazing).

0 · Reply

PeakedSeller Mar. 14 at 1:06 PM

$EVH 🚀 this is a screaming buy at these levels! Evolent Health just dropped strong Q4 beats and is guiding ~30% revenue growth in 2026 to ~$2.5B midpoint — powered by oncology dominance (heading to 65% mix), massive new enhanced contracts, and 90%+ shift to high-margin Performance Suite. Add 98% customer retention, AI cost savings, and conservative guidance that sets up a huge H2 EBITDA ramp… THE RECOVERY FOR THIS STOCK WILL BE VIOLENT!!! Value-based care is exploding — $EVH is perfectly positioned to win big. Dip buyers loading up! 💥📈 #EVH #HealthcareStocks #ValueBasedCare

0 · Reply

St0ckJunkie13 Mar. 13 at 5:56 PM

$EVH hitting the floor, cant realistically see profit until 2028

1 · Reply

PatBtmn Mar. 13 at 5:42 PM

$EVH ouch

0 · Reply

TOMKiLA Mar. 12 at 1:43 PM

$EVH a range between 2.5 and 3.5$ is the best opportunity for us because in the coming 12/18/24 months everything will change. The margin are still lower than the forecast, the new contract should increase the value of ebitda quickly For example, evolent signed a deal for 550m $ in 2026 and $800M in 2027. It’s the same contract but the value will be higher in 2027. Imagine how much money evolent should made within 2 years with 20/30 new contracts

1 · Reply

Market Cap	298.07M
Revenue (ttm)	1.88B
Net Income (ttm)	-534.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28.49%
Debt to Equity Ratio	2.34

Volume	4,445,300
Avg Vol	3,269,638
Day's Range	N/A - N/A
Shares Out	111.64M
Stochastic %K	5%
Beta	0.24
Analysts	Strong Sell
Price Target	$5.61